vutrisiran
Amvuttra
Pharmaceutical company: Alnylam Pharmaceuticals
Pharmacologic classification:Anti-transthyretin small interfering RNA agent
Therapeutic classification:Protein inhibitor
AVAILABLE FORMS
Injection: 25 mg/0.5 mL prefilled syringe
INDICATIONS AND DOSAGES
Polyneuropathy of hereditary transthyretin-mediated amyloidosis
Adults: 25 mg subcut every three months.
CONTRAINDICATIONS AND CAUTIONS
- This drug hasn’t been studied in those with severe renal impairment, end-stage renal disease, or moderate to severe hepatic impairment.
- Safety and effectiveness in children haven’t been established.
- Dialyzable drug: Unknown.
PREGNANCY-LACTATION-REPRODUCTION
- There are no available data on use during pregnancy. Use in pregnancy only if the benefit clearly outweighs the fetal risk.
- There is no information regarding the presence of this drug in human milk, the effects on the breastfed infant, or the effects on milk production. Use cautiously during breastfeeding.
INTERACTIONS
None reported.
ADVERSE REACTIONS
CV: AV block.
Metabolic: decreased vitamin A.
Musculoskeletal: arthralgia.
Respiratory: dyspnea.
Skin: injection site reactions (bruising, erythema, pain, pruritus, warmth).
Other: anti-drug antibody development.
Reactions in bold italics are life-threatening.
Released: November 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer